These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1703780)

  • 1. The relationship between clinical and biochemical changes following neuroleptic treatment in schizophrenia.
    Cooper SJ; Leahey W; Liddle J; King DJ
    Schizophr Res; 1990; 3(4):261-7. PubMed ID: 1703780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.
    Breslin NA; Suddath RL; Bissette G; Nemeroff CB; Lowrimore P; Weinberger DR
    Schizophr Res; 1994 Apr; 12(1):35-41. PubMed ID: 7517175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lithium prevents adaptation of brain dopamine systems to haloperidol in schizophrenic patients.
    Sternberg DE; Bowers MB; Heninger GR; Charney DS
    Psychiatry Res; 1983 Oct; 10(2):79-86. PubMed ID: 6581492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment.
    Kahn RS; Davidson M; Knott P; Stern RG; Apter S; Davis KL
    Arch Gen Psychiatry; 1993 Aug; 50(8):599-605. PubMed ID: 7688208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited.
    van Kammen DP; Peters J; Yao J; van Kammen WB; Neylan T; Shaw D; Linnoila M
    Arch Gen Psychiatry; 1990 Feb; 47(2):161-8. PubMed ID: 1689140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Changes in the CSF levels of monoamine metabolites in 102 chronic schizophrenic patients following probenecid before and after neuroleptic medication].
    Chen YF
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1984 Oct; 17(5):273-7. PubMed ID: 6085683
    [No Abstract]   [Full Text] [Related]  

  • 7. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.
    van Kammen DP; Agren H; Yao JK; O'Connor DT; Gurklis J; Peters JL
    Am J Psychiatry; 1994 Mar; 151(3):379-84. PubMed ID: 7509126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics.
    Hsiao JK; Colison J; Bartko JJ; Doran AR; Konicki PE; Potter WZ; Pickar D
    Arch Gen Psychiatry; 1993 Aug; 50(8):606-14. PubMed ID: 7688209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of electroconvulsive therapy on CSF amine metabolites in schizophrenic patients.
    Cooper SJ; Leahey W; Green DF; King DJ
    Br J Psychiatry; 1988 Jan; 152():59-63. PubMed ID: 2458796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melperone in the treatment of schizophrenia.
    Bjerkenstedt L
    Acta Psychiatr Scand Suppl; 1989; 352():35-9. PubMed ID: 2479227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant monoamine metabolite levels in CSF and family history of schizophrenia. Their relationships in schizophrenic patients.
    Sedvall GC; Wode-Helgodt B
    Arch Gen Psychiatry; 1980 Oct; 37(10):1113-6. PubMed ID: 6158928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF chromogranin A-like immunoreactivity in schizophrenia. Assessment of clinical and biochemical relationships.
    van Kammen DP; Peters J; Yao J; Neylan T; Beuger M; Pontius E; O'Connor DT
    Schizophr Res; 1991 Dec; 6(1):31-9. PubMed ID: 1723893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia.
    van Kammen DP; Kelley ME; Gurklis JA; Gilbertson MW; Yao JK; Peters JL
    Arch Gen Psychiatry; 1995 Aug; 52(8):673-8. PubMed ID: 7543265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics.
    Duncan E; Wolkin A; Angrist B; Sanfilipo M; Wieland S; Cooper TB; Rotrosen J
    Biol Psychiatry; 1993 Oct; 34(8):523-8. PubMed ID: 8274579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
    Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
    Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide.
    Roy A; Ninan P; Mazonson A; Pickar D; Van Kammen D; Linnoila M; Paul SM
    Psychol Med; 1985 May; 15(2):335-40. PubMed ID: 2410941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are monoamine metabolites in cerebrospinal fluid worth measuring?
    Potter WZ; Manji HK
    Arch Gen Psychiatry; 1993 Aug; 50(8):653-6. PubMed ID: 7688211
    [No Abstract]   [Full Text] [Related]  

  • 18. Perspectives on a time-dependent model of neuroleptic action.
    Pickar D
    Schizophr Bull; 1988; 14(2):255-68. PubMed ID: 2904694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.
    van Kammen DP; Peters J; van Kammen WB; Nugent A; Goetz KL; Yao J; Linnoila M
    Biol Psychiatry; 1989 Jun; 26(2):176-88. PubMed ID: 2472177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics.
    Csernansky JG; Newcomer JW; Jackson K; Lombrozo L; Faull KF; Zipursky R; Pfefferbaum A; Faustman WO
    Psychopharmacology (Berl); 1994 Nov; 116(3):291-6. PubMed ID: 7534423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.